Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

GLA Antikörper (AA 101-200)

GLA Reaktivität: Human, Maus, Ratte WB, ELISA, FACS, IHC (p), IF (cc), IF (p), IHC (fro) Wirt: Kaninchen Polyclonal unconjugated
Produktnummer ABIN872875
  • Target Alle GLA Antikörper anzeigen
    GLA (Galactosidase, alpha (GLA))
    Bindungsspezifität
    • 15
    • 5
    • 5
    • 5
    • 4
    • 4
    • 4
    • 4
    • 3
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 101-200
    Reaktivität
    • 69
    • 34
    • 25
    • 4
    • 4
    • 4
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Human, Maus, Ratte
    Wirt
    • 79
    • 8
    • 2
    Kaninchen
    Klonalität
    • 82
    • 7
    Polyklonal
    Konjugat
    • 35
    • 13
    • 11
    • 6
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Dieser GLA Antikörper ist unkonjugiert
    Applikation
    • 64
    • 31
    • 16
    • 16
    • 12
    • 12
    • 7
    • 7
    • 6
    • 5
    • 4
    • 3
    • 2
    • 1
    Western Blotting (WB), ELISA, Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))
    Kreuzreaktivität
    Human, Maus, Ratte
    Homologie
    Dog,Cow,Pig,Rabbit
    Aufreinigung
    Purified by Protein A.
    Immunogen
    KLH conjugated synthetic peptide derived from human Galactosidase alpha
    Isotyp
    IgG
    Top Product
    Discover our top product GLA Primärantikörper
  • Applikationshinweise
    WB 1:300-5000
    ELISA 1:500-1000
    FCM 1:20-100
    IHC-P 1:200-400
    IHC-F 1:100-500
    IF(IHC-P) 1:50-200
    IF(IHC-F) 1:50-200
    IF(ICC) 1:50-200
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    1 μg/μL
    Buffer
    0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
    Konservierungsmittel
    ProClin
    Vorsichtsmaßnahmen
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
    Lagerung
    4 °C,-20 °C
    Informationen zur Lagerung
    Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
    Haltbarkeit
    12 months
  • Target
    GLA (Galactosidase, alpha (GLA))
    Andere Bezeichnung
    Galactosidase alpha (GLA Produkte)
    Synonyme
    GALA antikoerper, Ags antikoerper, zgc:101584 antikoerper, MGC130872 antikoerper, SMU.877 antikoerper, SCF11.21 antikoerper, AO090005000217 antikoerper, alpha-GAL antikoerper, galactosidase alpha antikoerper, galactosidase, alpha antikoerper, galactosidase alpha S homeolog antikoerper, alpha-galactosidase antikoerper, aga antikoerper, alpha-galactosidase A antikoerper, GLA antikoerper, Gla antikoerper, gla antikoerper, gla.S antikoerper, agaN antikoerper, aga antikoerper, agaL antikoerper, SCO0541 antikoerper, rafA antikoerper, melA antikoerper, galA antikoerper, ANI_1_2528074 antikoerper, ANI_1_1502124 antikoerper, AOR_1_390174 antikoerper, CpipJ_CPIJ002066 antikoerper, MCYG_00962 antikoerper, MCYG_00791 antikoerper, Tsp_02909 antikoerper, Tsp_02508 antikoerper
    Hintergrund

    Synonyms: GALA, Alpha-galactosidase A, Alpha-D-galactosidase A, Alpha-D-galactoside galactohydrolase, Melibiase, GLA

    Background: Galactosidase alpha is involved in the hydrolysis of terminal, non reducing alpha D galactose residues in alpha D galactosides, including galactose oligosaccharides, galactomannans and galactohydrolase. Defects in GLA are the cause of Fabry's disease (FD). FD is a rare X-linked sphingolipidosis disease where glycolipid accumulates in many tissues. Clinical recognition in males results from characteristic skin lesions (angiokeratomas) over the lower trunk. Patients may show ocular deposits, febrile episodes, and burning pain in the extremities. Death results from renal failure, cardiac or cerebral complications of hypertension or other vascular disease. Heterozygous females may exhibit the disorder in an attenuated form, they are more likely to show corneal opacities.

    Gen-ID
    2717
    UniProt
    P06280
    Pathways
    SARS-CoV-2 Protein Interaktom
Sie sind hier:
Kundenservice